Evidence map›Paper›PMID 34208653›Full record

ArticleBrain sciences2021

Let Me See: Correlation between 5-ALA Fluorescence and Molecular Pathways in Glioblastoma: A Single Center Experience.

Francesco Maria Calamo Specchia, Matteo Monticelli, Pietro Zeppa, Andrea Bianconi, Francesco Zenga, Roberto Altieri, Beatrice Pugliese, Giuseppe Di Perna, Fabio Cofano, Fulvio Tartara and 5 more

Open access · goldAbstract read
In one paragraph

Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Francesco Maria Calamo SpecchiaUOC Neurosurgery, Head and Neck Department, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, Italy.
Matteo MonticelliNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.ORCID 0000-0002-3738-5106
Pietro ZeppaNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.
Andrea BianconiNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.ORCID 0000-0002-1014-0731
Francesco ZengaNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.ORCID 0000-0001-5440-3276
Roberto AltieriDepartment of Neurological Surgery, Policlinico "G. Rodolico", University Hospital, 95124 Catania, Italy.
Beatrice PuglieseNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.
Giuseppe Di PernaNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.ORCID 0000-0002-7381-9194
Fabio CofanoNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.
Fulvio TartaraNeurosurgery Unit, Istituto Clinico Città Studi, 20131 Milan, Italy.
Luca BerteroPathology Unit, AOC Città della Salute e della Scienza, 10126 Turin, Italy.ORCID 0000-0001-9887-7668
Paola CassoniPathology Unit, AOC Città della Salute e della Scienza, 10126 Turin, Italy.
Antonio MelcarneNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.
Michele Maria LanotteNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.ORCID 0000-0002-4184-028X
Diego GarbossaNeurosurgery Unit, AOC Città della Salute e della Scienza, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Turin, Italy.
University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITIstituto di Sessuologia Clinica · ITOspedale di Parma · ITPoliclinico Universitario di Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the aggressiveness of multimodal treatment, glioblastoma (GBM) is still a challenge for neurosurgeons, neurooncologists, and radiotherapists. A surgical approach is still a cornerstone in GBM therapeutic management, as the extent of resection is strongly related both to overall survival and progression-free survival. From this perspective, the use of photodynamic molecules could represent an interesting tool to achieve maximal and safe resection. Being able to trace the lesion's edges, indeed, could allow to improve the extent of resection and to minimize residual tumor while sparing normal tissue. The use of 5-aminolevulinic acid (5-ALA) as a photodynamic tracer is well established due to its strict correlation both with cellularity and metabolic activity of the GBM cell clones.

objectiveOur study aims to define whether a different molecular asset of GBM (especially investigating

methodsPatients undergoing surgery for GBM removal at our Institute (Dep. Of Neurosurgery, Ospedale Città della Salute e della Scienza, University of Turin, Italy) were retrospectively reviewed. Patients with histological diagnosis confirmation and to whom 5-ALA was given before surgery were included. The whole surgical procedure was recorded and then analyzed by three different people (a medical student, a resident, and a senior surgeon with an interest in neurooncology and experience in using 5-ALA) and a score was assigned to the different degrees of intraoperative fluorescence. The degree of fluorescence was then matched with the genotype.

resultsA trend of grade 2 fluorescence (i.e., "strong") was observed in the

conclusionOur results do not support the use of 5-ALA as a diagnostic tool, or a way to substitute the molecular profiling, but confirm 5-ALA as a powerful metabolic tracer, able to easily detect the pathological cells, especially in the IDH WT genotype, and in this perspective, further studies will be necessary to better describe the metabolic activity of GBM cells.

Indexed as

5-ALAextent of resectionfluorescenceglioblastomaIDH1MGMTmolecular pathways

Identifiers

PMID34208653
PMCPMC8235669
OpenAlexW3169370329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.